Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.98+0.20 (+0.92%)
Close on Nov 12, 2026Market cap $2.08BP/E –Yield –
Replimune market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Replimune's market cap was $1.83B on Nov 11, 2026, against $784.03M a year earlier. Over the last 5 years it ranged from $204.65M to $1.83B, with a median of $803.33M.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.83B | +140.0% |
| 2025 | Dec 31, 2025 | $762.08M | -8.0% |
| 2024 | Dec 31, 2024 | $828.26M | +66.4% |
| 2023 | Dec 29, 2023 | $497.87M | -63.2% |
| 2022 | Dec 30, 2022 | $1.35B | +6.5% |
| 2021 | Dec 31, 2021 | $1.27B | -17.4% |
| 2020 | Dec 31, 2020 | $1.54B | +237.9% |
| 2019 | Dec 31, 2019 | $455.17M | +44.3% |
| 2018 | Dec 31, 2018 | $315.54M | – |
See a number that looks wrong?